PTM.AX - Platinum Investment Management Limited
ASX - ASX Delayed price. Currency in AUD
At close: 04:10PM AEST
Stock chart is not supported by your current browser
| Previous close | 1.7300 |
| Open | 1.7200 |
| Bid | 1.7150 x 999400 |
| Ask | 1.7400 x 1370800 |
| Day's range | 1.7050 - 1.7400 |
| 52-week range | 1.5525 - 2.3350 |
| Volume | |
| Avg. volume | 901,538 |
| Market cap | 1.021B |
| Beta (5Y monthly) | 1.22 |
| PE ratio (TTM) | 12.43 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.14 (8.12%) |
| Ex-dividend date | 02 Mar 2023 |
| 1y target est | N/A |
- GlobeNewswire
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measuresEuropean Commission decision on marketing authorization application (MAA) expected in approximately 60 days If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG) Breda, the Netherlands—June 24, 2022—argenx (Eur
